New Vision-Saving injection enters final testing phase

This study is testing whether a new eye injection called QL1207H works as well as the established drug Eylea for treating wet age-related macular degeneration, a leading cause of vision loss in older adults. About 356 patients aged 50+ with active disease will receive injections in their eye and have their vision tracked. The goal is to see if the new treatment provides similar vision improvement and safety with potentially fewer injections over time.